Veltassa® (patiromer) approved in Japan for the treatment of adults with hyperkalemia

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Vifor-Veltassa

More Like This

PR Newswire associated0

CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy

PR Newswire associated0

CSL Vifor and Travere Therapeutics Announce Swissmedic approval of FILSPARI® (sparsentan) for the treatment of IgA Nephropathy

PR Newswire associated0

England's NICE recommends FILSPARI® (sparsentan) as a treatment option for IgA nephropathy

MORE PATIENTS ACROSS ENGLAND AND WALES ARE SET TO BECOME ELIGIBLE FOR ASTRAZENECA’S FORXIGA (DAPAGLIFLOZIN) FOR THE TREATMENT OF CHRONIC KIDNEY DISEASE

Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera

Alnylam Presents Positive Results from the KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development for the Treatment of Hypertension in Patients at High Cardiovascular Risk

Alnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran is Added to Standard of Care Antihypertensives

European Medicines Agency Accepts Deciphera’s Marketing Authorization Application for Vimseltinib for Treatment of Patients with Tenosynovial Giant Cell Tumor (TGCT)